Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Opaleye Management Inc.

Q2 2023 · 13F-HR

Opaleye Management Inc.holdings as filed

Filed 2023-08-14 · accession 0001493152-23-028636

$418.1M
Reported value
47
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
00445A100ACELYRIN INC$86.9M20.8%4,158,638CommonSOLE
415858109HROWHARROW HEALTH INC$71.9M17.2%3,775,000CommonSOLE
67576A100OCULOCULAR THERAPEUTIX INC$29.8M7.13%5,780,000CommonSOLE
872381108TELATELA BIO INC$16.0M3.83%1,580,000CommonSOLE
22663K107CRNXCRINETICS PHARMACEUTICALS INC$15.2M3.64%845,000CommonSOLE
492327101KROSKEROS THERAPEUTICS INC$14.2M3.39%352,650CommonSOLE
G1110E107BHVNBIOHAVEN LTD$12.9M3.09%540,000CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$12.1M2.90%735,000CommonSOLE
45166A102IDYAIDEAYA BIOSCIENCES INC$9.8M2.33%415,000CommonSOLE
617760202MOR2MORPHOSYS AG$9.0M2.16%1,209,380CommonSOLE
92243G108PCVXVAXCYTE INC$8.8M2.11%177,000CommonSOLE
29772L108ETONETON PHARMACEUTICALS INC$8.0M1.91%2,285,000CommonSOLE
374163103GERNGERON CORP$7.5M1.80%2,350,000CommonSOLE
56854Q200MRNS*MARINUS PHARMACEUTICALS INC$6.8M1.62%625,000CommonSOLE
483497103KALVKALVISTA PHARMACEUTICALS INC$6.5M1.55%720,000CommonSOLE
74365U107TARAPROTARA THERAPEUTICS INC$6.4M1.54%2,692,594CommonSOLE
28036F105EWTXEDGEWISE THERAPEUTICS INC$6.3M1.51%815,000CommonSOLE
23257D103CBAYUSDCYMABAY THERAPEUTICS INC$6.2M1.48%566,700CommonSOLE
M96088105URGNUROGEN PHARMA LTD$5.9M1.41%570,000CommonSOLE
G8807B106TBPHTHERAVANCE BIOPHARMA INC$5.6M1.35%543,500CommonSOLE
88369M101THESEUS PHARMACEUTICALS INC$5.6M1.33%597,500CommonSOLE
004225108ACADACADIA PHARMACEUTICALS INC$5.2M1.24%217,000CommonSOLE
45826J105NTLAINTELLIA THERAPEUTICS INC$4.9M1.17%120,000CommonSOLE
53635D202LQDALIQUIDIA CORPORATION$4.5M1.07%570,700CommonSOLE
517125100LRMRLARIMAR THERAPEUTICS INC$4.4M1.04%1,390,000CommonSOLE
23282W605CYTKCYTOKINETICS INC$4.2M1.01%130,000CommonSOLE
89532M101TRVITREVI THERAPEUTICS INC$4.1M0.97%1,701,500CommonSOLE
38341P102GOSSGOSSAMER BIO INC$4.0M0.97%3,370,000CommonSOLE
35104E100FDMT4D MOLECULAR THERAPEUTICS INC$4.0M0.96%221,700CommonSOLE
B6S7WD106NYXHNYXOAH S A$3.6M0.85%445,000CommonSOLE
268311107EDAPEDAP TMS S A$3.5M0.84%380,000CommonSOLE
48576U106KPTIEURKARYOPHARM THERAPEUTICS INC$3.2M0.76%1,785,000CommonSOLE
462260100IOVAIOVANCE BIOTHERAPEUTICS INC$3.0M0.71%421,000CommonSOLE
85916J409STXSSPECTRUM PHARMACEUTICALS$3.0M0.71%3,074,995CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$2.5M0.61%305,000CommonSOLE
192005106CDXSCODEXIS INC$1.9M0.45%675,000CommonSOLE
34960Q109FORTRESS BIOTECH INC$1.8M0.44%3,310,000CommonSOLE
869367102SUTRO BIOPHARMA INC$1.4M0.34%307,000CommonSOLE
09203E105BDTXBLACK DIAMOND THERAPEUTICS$1.4M0.33%275,000CommonSOLE
89237H209TRACON PHARMACEUTICALS INC$1.4M0.33%4,764,508CommonSOLE
N71542109PRQRPROQR THERAPEUTICS NV$1.1M0.25%653,000CommonSOLE
481116101JASPER$917,8230.22%669,944CommonSOLE
92337C203VSTMVERASTEM INC$758,8800.18%102,000CommonSOLE
98419J206XOMAXOMA CORP DEL$594,7500.14%275,000CommonSOLE
4495851081K0IGM BIOSCIIENCES INC$586,1050.14%63,500CommonSOLE
359616109FULCFULCRUM THERAPEUTICS INC$473,8800.11%143,600CommonSOLE
49372L100KEZAR LIFE SCIENCES INC$242,0500.06%98,796CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.